Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Viatris faces downside risk from regulatory challenges, macro headwinds, and muted growth. Click to learn more on why VTRS ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP ...

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

Learn about Ozempic and Wegovy, two medications making waves in weight management. Discover how they work, their benefits, ...

So-called ‘skinny jabs’ are being prescribed to people who don’t need them, with terrifying side effects. How did our ...